Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) shares rose 5.6% during mid-day trading on Friday . The stock traded as high as $152.66 and last traded at $151.78, with a volume of 383,724 shares traded. The stock had previously closed at $143.75.

Several research analysts recently weighed in on the stock. Vetr raised shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating and set a $147.31 target price for the company in a research note on Monday, April 11th. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Wednesday, June 1st. Goldman Sachs Group Inc. boosted their target price on shares of Intercept Pharmaceuticals from $114.00 to $128.00 and gave the company a “neutral” rating in a research note on Tuesday, May 31st. Morgan Stanley reissued a “sell” rating on shares of Intercept Pharmaceuticals in a research note on Saturday, April 9th. Finally, Robert W. Baird reissued an “outperform” rating and issued a $332.00 target price on shares of Intercept Pharmaceuticals in a research note on Wednesday, June 1st. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the company. Intercept Pharmaceuticals has an average rating of “Hold” and a consensus target price of $203.08.

The firm’s market cap is $3.73 billion. The stock’s 50-day moving average price is $147.36 and its 200 day moving average price is $133.95.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($5.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($3.60) by $1.57. During the same quarter in the previous year, the business earned ($1.78) earnings per share. On average, equities research analysts anticipate that Intercept Pharmaceuticals Inc. will post ($16.77) earnings per share for the current year.

In other Intercept Pharmaceuticals news, CEO Mark Pruzanski sold 714 shares of the firm’s stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $145.11, for a total value of $103,608.54. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Lisa Bright sold 251 shares of the firm’s stock in a transaction that occurred on Wednesday, May 25th. The shares were sold at an average price of $137.50, for a total value of $34,512.50. Following the completion of the sale, the insider now directly owns 18,855 shares in the company, valued at approximately $2,592,562.50. The disclosure for this sale can be found here.

Other hedge funds have added to or reduced their stakes in the company. California State Teachers Retirement System raised its stake in Intercept Pharmaceuticals by 1.4% in the fourth quarter. California State Teachers Retirement System now owns 29,529 shares of the biopharmaceutical company’s stock worth $4,410,000 after buying an additional 400 shares during the period. Rhumbline Advisers raised its stake in shares of Intercept Pharmaceuticals by 0.7% in the fourth quarter. Rhumbline Advisers now owns 15,849 shares of the biopharmaceutical company’s stock valued at $2,367,000 after buying an additional 109 shares during the last quarter. Profund Advisors LLC raised its stake in shares of Intercept Pharmaceuticals by 0.5% in the fourth quarter. Profund Advisors LLC now owns 12,113 shares of the biopharmaceutical company’s stock valued at $1,809,000 after buying an additional 65 shares during the last quarter. ProShare Advisors LLC raised its stake in shares of Intercept Pharmaceuticals by 5.9% in the fourth quarter. ProShare Advisors LLC now owns 20,213 shares of the biopharmaceutical company’s stock valued at $3,019,000 after buying an additional 1,130 shares during the last quarter. Finally, New York State Common Retirement Fund raised its stake in shares of Intercept Pharmaceuticals by 2.2% in the fourth quarter. New York State Common Retirement Fund now owns 37,400 shares of the biopharmaceutical company’s stock valued at $5,586,000 after buying an additional 800 shares during the last quarter.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Company’s product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.